Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management · Journal article
International Journal of Medical & Pharmaceutical Sciences · September 7, 2026
A consensus or society position rather than new primary data.
This narrative review evaluates GLP-1 receptor agonist efficacy for weight management across populations with and without type 2 diabetes, synthesizing evidence from pivotal trials of liraglutide and semaglutide. The review concludes that GLP-1 RAs produce clinically meaningful weight reduction accompanied by improvements in cardiometabolic outcomes, but emphasises heterogeneous treatment response, safety concerns (gastrointestinal effects, weight regain post-withdrawal), and the need for individualized patient selection and long-term multidisciplinary care alongside lifestyle intervention.
Narrative review. Adults with overweight or obesity, with and without type 2 diabetes mellitus. Intervention: Glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and newer incretin-based approaches).
Pivotal trials of liraglutide and semaglutide demonstrate clinically meaningful reductions in body weight Weight reduction is accompanied by improvements in glycaemic control, cardiometabolic risk factors, physical function and health-related quality of life Treatment response is heterogeneous with important concerns regarding gastrointestinal adverse effects, treatment discontinuation, and weight regain after withdrawal
No quantification of adverse event rates, discontinuation rates, or weight regain magnitude after withdrawal Treatment response is heterogeneous with important concerns regarding gastrointestinal adverse effects, treatment discontinuation, and weight regain after withdrawal
Clinicians should consider GLP-1 RAs as a pharmacological option for chronic weight management in appropriate patients, but must individualise selection, monitor safety closely (especially gastrointestinal tolerability), counsel on weight regain risk after discontinuation, and integrate pharmacotherapy with mandatory lifestyle intervention and long-term support.
A narrative review synthesizing evidence from pivotal trials to provide clinical recommendations on GLP-1 agonist use for weight management, addressing efficacy, safety and individualized patient selection.
As stated by the source record.
Clinicians should consider GLP-1 RAs as a pharmacological option for chronic weight management in appropriate patients, but must individualise selection, monitor safety closely (especially gastrointestinal tolerability), counsel on weight regain risk after discontinuation, and integrate pharmacotherapy with mandatory lifestyle intervention and long-term support.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is a chronic, relapsing metabolic disease associated with substantial morbidity, mortality and healthcare burden. Although dietary modification, physical activity and behavioural therapy remain fundamental to treatment, long-term maintenance of clinically meaningful weight loss is difficult for many individuals. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed for type 2 diabetes mellitus but have become major pharmacological options for chronic weight management because they reduce appetite, increase satiety, delay gastric emptying and improve glucose-dependent metabolic regulation. This review evaluates the efficacy of GLP-1-based therapies for weight management in adults with overweight or obesity, with particular attention to differences between populations with and without type 2 diabetes. Evidence from pivotal trials of liraglutide and semaglutide demonstrates clinically meaningful reductions in body weight, while newer incretin-based approaches have broadened the therapeutic landscape. Weight reduction is accompanied by improvements in glycaemic control, cardiometabolic risk factors, physical function and health-related quality of life. However, treatment response is heterogeneous and important concerns remain regarding gastrointestinal adverse effects, treatment discontinuation, weight regain after withdrawal, preservation of lean mass, long-term adherence, affordability and access. Lifestyle intervention remains an essential component of pharmacotherapy. Overall, GLP-1 RAs represent a major advance in obesity management, but optimal outcomes require individualized patient selection, ongoing safety monitoring and long-term multidisciplinary care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.